Abstract
Since cell death by apoptosis plays a key role in the regulation of tissue homeostasis, any defect in this intrinsic death program may result in tumor formation. "Inhibitor of apoptosis proteins" (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting effector caspases. Aberrant expression and/or function of IAPs have been implied to be involved in the pathogenesis and progression of various human diseases including cancer, autoimmune disorders or neurodegeneration. Recent insights into the regulation of IAPs have provided the basis for various exciting discoveries aimed at modulating expression or dysfunction of IAPs. Thus, targeting IAPs, e.g. by antisense approaches, RNA interference or small molecules, may proof to be a novel strategy for the diagnosis and treatment of human diseases.
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Inhibitor of Apoptosis Proteins (IAPs) for Diagnosis and Treatment of Human Diseases
Volume: 1 Issue: 1
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, IAP, Smac, survivin, caspases
Abstract: Since cell death by apoptosis plays a key role in the regulation of tissue homeostasis, any defect in this intrinsic death program may result in tumor formation. "Inhibitor of apoptosis proteins" (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting effector caspases. Aberrant expression and/or function of IAPs have been implied to be involved in the pathogenesis and progression of various human diseases including cancer, autoimmune disorders or neurodegeneration. Recent insights into the regulation of IAPs have provided the basis for various exciting discoveries aimed at modulating expression or dysfunction of IAPs. Thus, targeting IAPs, e.g. by antisense approaches, RNA interference or small molecules, may proof to be a novel strategy for the diagnosis and treatment of human diseases.
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Targeting Inhibitor of Apoptosis Proteins (IAPs) for Diagnosis and Treatment of Human Diseases, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246539
DOI https://dx.doi.org/10.2174/157489206775246539 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways
Current Drug Targets The Role of Patterned Hydrophilic Domains in Nanoparticle-Membrane Interactions
Current Nanoscience Lung Cancer Vaccines
Current Gene Therapy Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Current Drug Delivery Recent Advances in Multinuclear Complexes as Potential Anticancer and DNA Binding Agents
Anti-Cancer Agents in Medicinal Chemistry The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery)
Current Pharmaceutical Design UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology N-Succinyl Chitosan as Buccal Penetration Enhancer for Delivery of Herbal Agents in Treatment of Oral Mucositis
Current Drug Delivery Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine